4D Molecular Therapeutics (NASDAQ:FDMT) Raised to “Hold” at Wall Street Zen

4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Other analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Friday. Barclays began coverage on 4D Molecular Therapeutics in a report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 price objective on the stock. Royal Bank Of Canada boosted their price objective on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.71.

4D Molecular Therapeutics Trading Down 4.1%

FDMT stock opened at $8.61 on Friday. The firm has a 50-day moving average price of $8.75 and a 200-day moving average price of $9.10. 4D Molecular Therapeutics has a 12 month low of $2.23 and a 12 month high of $12.34. The stock has a market capitalization of $439.54 million, a P/E ratio of -3.56 and a beta of 2.99.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.96. The company had revenue of $85.09 million for the quarter, compared to analyst estimates of $30.86 million. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. As a group, equities analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of FDMT. Dynamic Technology Lab Private Ltd acquired a new stake in shares of 4D Molecular Therapeutics during the first quarter worth $39,000. Wexford Capital LP bought a new position in 4D Molecular Therapeutics during the third quarter worth $41,000. Quadrature Capital Ltd acquired a new position in 4D Molecular Therapeutics in the second quarter valued at $42,000. Farther Finance Advisors LLC boosted its position in 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after acquiring an additional 2,674 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in 4D Molecular Therapeutics during the first quarter valued at $46,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

Key 4D Molecular Therapeutics News

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: High-profile firms reiterated bullish views and raised targets, supporting upside potential — HC Wainwright reaffirmed a “buy” and set a $36 target (very large implied upside). Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $35 and gave an “outperform” rating, signaling strong analyst conviction on mid/long-term value. Read More.
• Positive Sentiment: Chardan Capital reaffirmed a “buy” with a $26 target, adding another supportive research note. Read More.
• Positive Sentiment: Fundamental beat: 4D reported Q4 EPS of $0.43 (well ahead of consensus) and revenue of $85.1M, which typically supports higher valuations and reduces near-term execution risk. Read More.
• Neutral Sentiment: Analyst commentary is mixed across the sector; some aggregation pieces note divergent views on FDMT which can increase intraday volatility without clear directional pressure. Read More.
• Neutral Sentiment: Short-interest reports in the latest feeds show anomalous/zero values (reports indicate increases but list 0 shares/NaN), suggesting the data feed is unreliable — this appears to be noise rather than a clear short-squeeze or large shorting event.
• Negative Sentiment: Cantor Fitzgerald issued a “hold” on FDMT, which can dampen momentum from the bullish notes and makes the street’s view less one-sided. Read More.
• Negative Sentiment: New risk disclosure: a TipRanks piece highlights reimbursement and pricing pressures that could materially affect the commercial outlook for FDMT’s gene therapies — a real demand/price-risk that can weigh on valuation and near-term sentiment. Read More.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.